TxCell is developing innovative, personalized cell-based immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases.

TxCell's strategy is to target niche and orphan indications for which there are few or no treatment options.


The product candidates developed by TxCell consist of autologous antigen-specific type 1 regulatory T cells (Ag-Tregs) generated ex-vivo from patient's blood in a proprietary manufacturing process (link).


TxCell lead product candidate, Ovasave®, has successfully completed a phase I/II clinical trial in Crohn's disease patients, refractory to all current treatments, with promising results (link).

The next step in this program will be an international phase IIb clinical trial to confirm the positive phase I/II study results.


Txcell second product candidate, Col-Treg, is in development for Autoimmune Uveitis, a rare disease with very limited treatment options. The next step in this program will be a phase I/II proof of principle clinical trial.

Further product candidates for autoimmune inflammatory indications are in preclinical development.


February 11, 2014
Damian Marron CEO presented TxCell at the 16th BIO CEO & Investor Conference 2014, New York, US


January 28, 2014
Dr. Arnaud Foussat at Immunotherapy Forum
Washington, US
Cellular Immunotherapy of chronic inflammation and autoimmunity using autologous antigen-specific T regulatory (Treg) cells


January 15, 2014
Damian Marron CEO presented TxCell at Biotech Showcase 2014, San Francisco, US